Novo Nordisk and OpenAI forge major AI alliance to accelerate drug discovery & healthcare operations
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Subscribe To Our Newsletter & Stay Updated